Spasticity

7
Pipeline Programs
5
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
4
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
3 programs
3
SativexPhase 31 trial
Sativex®Phase 31 trial
Sativex®Phase 31 trial
Active Trials
NCT00702468Completed36Est. Jan 2009
NCT00711646Completed189Est. Mar 2004
NCT00681538Completed572Est. Jan 2009
Flowonix Medical
Flowonix MedicalNJ - Hackettstown
1 program
1
Prometra Programmable Implantable Pump SystemPhase 31 trial
Active Trials
NCT01051128Withdrawn0Est. Dec 2010
Saol Therapeutics
Saol TherapeuticsGA - Roswell
1 program
1
SL-1002Phase 21 trial
Active Trials
NCT05311215UnknownEst. Sep 2023
Ipsen
IpsenChina - Tianjin
3 programs
1
IPN10200Phase 1/21 trial
Adult Subjects Suffering From Lower Limb Spasticity Following StrokeN/A1 trial
Botulinum toxin type A injectionN/A1 trial
Active Trials
NCT01444794Completed100Est. Feb 2013
NCT04673240Unknown70Est. Jun 2022
NCT04752774Recruiting240Est. Oct 2027
Teva
TevaIsrael - Petach Tikva
1 program
1
sublingual tizanidine 12 mgPhase 1/21 trial
Active Trials
NCT00464958Terminated10Est. Dec 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Flowonix MedicalPrometra Programmable Implantable Pump System
Jazz PharmaceuticalsSativex®
Jazz PharmaceuticalsSativex
Jazz PharmaceuticalsSativex®
Saol TherapeuticsSL-1002
IpsenIPN10200
Tevasublingual tizanidine 12 mg
IpsenBotulinum toxin type A injection
IpsenAdult Subjects Suffering From Lower Limb Spasticity Following Stroke

Clinical Trials (9)

Total enrollment: 1,217 patients across 9 trials

NCT01051128Flowonix MedicalPrometra Programmable Implantable Pump System

Continuous Intrathecal Baclofen Infusion for Chronic Spasticity

Start: Jan 2010Est. completion: Dec 20100
Phase 3Withdrawn
NCT00681538Jazz PharmaceuticalsSativex®

A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

Start: Jan 2008Est. completion: Jan 2009572 patients
Phase 3Completed
NCT00702468Jazz PharmaceuticalsSativex

Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis

Start: Nov 2007Est. completion: Jan 200936 patients
Phase 3Completed
NCT00711646Jazz PharmaceuticalsSativex®

A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.

Start: Jun 2002Est. completion: Mar 2004189 patients
Phase 3Completed
NCT05311215Saol TherapeuticsSL-1002

Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

Start: Apr 2022Est. completion: Sep 2023
Phase 2Unknown
NCT04752774IpsenIPN10200

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Start: Apr 2021Est. completion: Oct 2027240 patients
Phase 1/2Recruiting
NCT00464958Tevasublingual tizanidine 12 mg

One Year Extension Study To Protocol C2/5/TZ:MS-05

Start: Jan 2008Est. completion: Dec 200810 patients
Phase 1/2Terminated
NCT04673240IpsenBotulinum toxin type A injection

CLINICAL EFFECT OF BOTULINUM TOXIN TYPE A IN TREATMENT OF SPASTICITY

Start: Mar 2019Est. completion: Jun 202270 patients
N/AUnknown
NCT01444794IpsenAdult Subjects Suffering From Lower Limb Spasticity Following Stroke

Adult Subjects Suffering From Lower Limb Spasticity Following Stroke

Start: Sep 2011Est. completion: Feb 2013100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,217 patients
5 companies competing in this space